The total return over the past 12 months is -43.26% vs. +16.94% for the S&P 500. So far it's up -50.21% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (43.26%) | 0.00% | (42.70%) | N/A | N/A | N/A |
| Total Return CAGR | (43.26%) | 0.00% | (42.70%) | N/A | N/A | N/A |
| Revenue CAGR | (6.98%) | (6.30%) | +22.93% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | (13.15%) | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | (13.29%) | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Spero Therapeutics, Inc. (SPRO)
| Year | Start price | End price | SPRO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.33 | $1.16 | (50.21%) | +14.51% | (64.72%) |
| 2025 | $1.03 | $2.33 | +126.21% | +17.72% | +108.49% |
| 2024 | $1.47 | $1.03 | (29.93%) | +24.89% | (54.82%) |
| 2023 | $1.73 | $1.47 | (15.03%) | +26.19% | (41.22%) |
| 2022 | $16.01 | $1.73 | (89.19%) | (18.17%) | (71.02%) |
| 2021 | $19.39 | $16.01 | (17.43%) | +28.74% | (46.17%) |
| 2020 | $9.62 | $19.39 | +101.56% | +18.37% | +83.19% |
| 2019 | $6.15 | $9.62 | +56.42% | +31.22% | +25.20% |
| 2018 | $11.75 | $6.15 | (47.66%) | (4.56%) | (43.10%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
